Literature DB >> 25805538

Embolization of metastatic neuroendocrine tumor resulting in clinical manifestations of syndrome of inappropriate secretion of antidiuretic hormone.

Hooman Yarmohammadi1, Joseph P Erinjeri2, Karen T Brown2.   

Abstract

Complications after hepatic artery embolization are usually minor and transient. This report describes a patient with a pancreatic neuroendocrine tumor with hepatic metastases who repeatedly developed clinical findings of syndrome of inappropriate secretion of antidiuretic hormone with hyponatremia (sodium < 130 mEq/L), low plasma osmolarity (< 275 mOsm/kg), and high urine osmolarity (> 500 mOsm/kg) after every session of hepatic artery embolization.
Copyright © 2015 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25805538      PMCID: PMC5066575          DOI: 10.1016/j.jvir.2014.11.032

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  15 in total

1.  Ectopic adrenalcorticotropic hormone syndrome improved by transarterial embolization to hepatic metastatic lesions of pancreatic neuroendocrine carcinoma: a case report.

Authors:  Hao-Wen Lin; Fen-Yu Tseng
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

2.  Karnofsky memorial lecture. An odyssey in the land of small tumors.

Authors:  C G Moertel
Journal:  J Clin Oncol       Date:  1987-10       Impact factor: 44.544

Review 3.  Therapeutic recommendations for management of severe hyponatremia: current concepts on pathogenesis and prevention of neurologic complications.

Authors:  A Soupart; G Decaux
Journal:  Clin Nephrol       Date:  1996-09       Impact factor: 0.975

Review 4.  Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small-cell lung cancer: case report and literature review.

Authors:  S L Vanhees; R Paridaens; J F Vansteenkiste
Journal:  Ann Oncol       Date:  2000-08       Impact factor: 32.976

5.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

6.  Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience.

Authors:  Sanjay Gupta; James C Yao; Kamran Ahrar; Michael J Wallace; Frank A Morello; David C Madoff; Ravi Murthy; Marshall E Hicks; Jaffer A Ajani
Journal:  Cancer J       Date:  2003 Jul-Aug       Impact factor: 3.360

7.  Hyponatremia and syndrome of inappropriate anti-diuretic hormone reported with the use of Vincristine: an over-representation of Asians?

Authors:  Isaac W Hammond; Jeffrey A Ferguson; Kenneth Kwong; Edmundo Muniz; Frank Delisle
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002 Apr-May       Impact factor: 2.890

Review 8.  Catheter-based treatments for hepatic metastases from neuroendocrine tumors.

Authors:  Kenneth J Kolbeck; Khashayar Farsad
Journal:  AJR Am J Roentgenol       Date:  2014-10       Impact factor: 3.959

9.  Transarterial liver-directed therapies of neuroendocrine hepatic metastases.

Authors:  Javier Nazario; Sanjay Gupta
Journal:  Semin Oncol       Date:  2010-04       Impact factor: 4.929

10.  Factors affecting periprocedural morbidity and mortality and long-term patient survival after arterial embolization of hepatic neuroendocrine metastases.

Authors:  Constantinos T Sofocleous; Elena N Petre; Mithat Gonen; Diane Reidy-Lagunes; Ivan K Ip; William Alago; Anne M Covey; Joseph P Erinjeri; Lynn A Brody; Majid Maybody; Raymond H Thornton; Stephen B Solomon; George I Getrajdman; Karen T Brown
Journal:  J Vasc Interv Radiol       Date:  2014-01       Impact factor: 3.682

View more
  2 in total

Review 1.  Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2016-09-23       Impact factor: 3.889

2.  Pancreatic neuroendocrine tumor producing vasopressin: A case report.

Authors:  Jingyan Li; Xinxin Zhang; Qing He; Wenli Feng; Li Ding; Zhuoqun Wang; Haonan Yu; Qiusong Chen; Ning Lu; Dongbo Xu; Jingqiu Cui
Journal:  Medicine (Baltimore)       Date:  2021-10-08       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.